相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway
Rosa Lapalombella et al.
BLOOD (2010)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
Sarah E. M. Herman et al.
BLOOD (2010)
Predictors of Competing Mortality in Advanced Head and Neck Cancer
Loren K. Mell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo
David M. Lucas et al.
BLOOD (2009)
Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia
Georg Aue et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
Rosa Lapalombella et al.
BLOOD (2008)
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
Alessandra Ferrajoli et al.
BLOOD (2008)
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia
Leslie A. Andritsos et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: Down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity
Syed-Rehan A. Hussain et al.
CLINICAL CANCER RESEARCH (2007)
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
Asher Chanan-Khan et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia
Amy J. Johnson et al.
BLOOD (2006)
Down-regulation of CD20 on B cells upon CD40 activation
J Anolik et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules
NE Kay et al.
LEUKEMIA (2002)
分享论文
